Laura Claire Price
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Claire Price has a total of 390 co-authors. Here are the top co-authors by number of shared publications:
Colm McCabe
National Pulmonary Hypertension Service, Royal Brompton Hospital Part of Guy's and St Thomas' NHS Foundation Trust London UK
16 shared publicationsAleksander Kempny
Guys & St Thomas NHS Fdn Trust, Royal Brompton & Harefield Hosp, Natl Pulm Hypertens Serv, London, England
8 shared publications- Konstantinos Dimopoulos
Adult Congenital Heart Centre and Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK
8 shared publications S. John Wort
National Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK
8 shared publicationsCarl Harries
National Pulmonary Hypertension Service, Royal Brompton Hospital Part of Guy's and St Thomas' NHS Foundation Trust London UK
6 shared publicationsKonstantinos Dimopoulos
National Pulmonary Hypertension Service, Royal Brompton Hospital Part of Guy's and St Thomas' NHS Foundation Trust London UK
6 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Pulmonary Arterial Hypertension Associated With Chronic Mephedrone Use: A Case Report
Mephedrone is a synthetic cathinone with sympathomimetic effects, but has not previously been linked to pulmonary arterial hypertension (PAH). We report a 42‐year‐old woman with no prior cardiopulmonary disease who presented with severe pre‐capillary PAH after a decade of near‐daily mephedrone use. Extensive evaluation—including autoimmune, infectious, genetic, and imaging studies—excluded recognised causes of PAH. Following cessation of mephedrone and initiation of dual oral PAH‐targeted therapy, she demonstrated substantial initial clinical and haemodynamic improvement; however, the response remained incomplete, necessitating further treatment escalation with selexipag. This appears to be the first reported case of PAH linked to mephedrone use.
- 1 October 2026
- Published by Wiley in Pulmonary Circulation
- Vol. 16 (4)
Open AccessPulmonary Arterial Hypertension Associated With Chronic Mephedrone Use: A Case Report
Mephedrone is a synthetic cathinone with sympathomimetic effects, but has not previously been linked to pulmonary arterial hypertension (PAH). We report a 42‐year‐old woman with no prior cardiopulmonary disease who presented with severe pre‐capillary PAH after a decade of near‐daily mephedrone use. Extensive evaluation—including autoimmune, infectious, genetic, and imaging studies—excluded recognised causes of PAH. Following cessation of mephedrone and initiation of dual oral PAH‐targeted therapy, she demonstrated substantial initial clinical and haemodynamic improvement; however, the response remained incomplete, necessitating further treatment escalation with selexipag. This appears to be the first reported case of PAH linked to mephedrone use.
Effect of Dietary Nitrate Supplementation on Exercise Performance in Hypoxic IPF (EDEN-OX3): a double-blind, placebo-controlled, randomised crossover study
Dietary nitrate (NO₃ − ) supplementation has been shown to improve vascular function and exercise capacity in chronic obstructive pulmonary disease and in pulmonary hypertension. In a double-blind, placebo-controlled crossover study in 20 patients with idiopathic pulmonary fibrosis who desaturated on exercise, endurance shuttle walk test improved by a median (IQR) difference of 31 s (–9.5 to 100.0; (p=0.043)), following a single dose of 140 mL NO₃ − rich beetroot juice, as did brachial artery flow mediated dilatation; +4.25% (95% CI –0.71% to 8.45%; p=0.036), compared with following placebo NO₃ − depleted placebo juice. Longer-term studies are needed to see if these acute effects translate into sustained benefit. ISRCTN14888729 . Registration date 14 July 2015, https://doi.org/10.1186/ISRCTN14888729
Effect of Dietary Nitrate Supplementation on Exercise Performance in Hypoxic IPF (EDEN-OX3): a double-blind, placebo-controlled, randomised crossover study
Dietary nitrate (NO₃ − ) supplementation has been shown to improve vascular function and exercise capacity in chronic obstructive pulmonary disease and in pulmonary hypertension. In a double-blind, placebo-controlled crossover study in 20 patients with idiopathic pulmonary fibrosis who desaturated on exercise, endurance shuttle walk test improved by a median (IQR) difference of 31 s (–9.5 to 100.0; (p=0.043)), following a single dose of 140 mL NO₃ − rich beetroot juice, as did brachial artery flow mediated dilatation; +4.25% (95% CI –0.71% to 8.45%; p=0.036), compared with following placebo NO₃ − depleted placebo juice. Longer-term studies are needed to see if these acute effects translate into sustained benefit. ISRCTN14888729 . Registration date 14 July 2015, https://doi.org/10.1186/ISRCTN14888729
- 7 May 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2600285
Vascular targeted therapies for fibrotic lung disease: start of a new era?
Shareable abstract The vasculature in lungs with pulmonary fibrosis shows signs of vasculopathy independent of hemodynamic PH-ILD. This viewpoint briefly summarizes the evidence that vasculopathy can drive fibrosis progression and that targeting it is highly promising
- 7 May 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2600285
Vascular targeted therapies for fibrotic lung disease: start of a new era?
Shareable abstract The vasculature in lungs with pulmonary fibrosis shows signs of vasculopathy independent of hemodynamic PH-ILD. This viewpoint briefly summarizes the evidence that vasculopathy can drive fibrosis progression and that targeting it is highly promising
- Top Cited PapersOpen Access
- 12 March 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2502651
Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review
Pulmonary hypertension (PH) is a common sequela of interstitial lung diseases (ILDs) and is associated with poor prognosis and quality of life. The diagnosis and management of PH associated with ILD (ILD-PH) are challenging, due in part to the heterogeneity of ILD subtypes, difficulty distinguishing symptoms and signs of ILD progression from manifestations of PH, lack of specific biomarkers, and the requirement of invasive right heart catheterisation (RHC) to diagnose and assess the severity of PH. This state-of-the-art review provides a comprehensive overview of the clinical characteristics, pathophysiology, diagnosis, prognosis and treatment of ILD-PH. It also identifies promising areas for future research, such as the development and validation of novel biomarkers and imaging techniques and further evaluation of the efficacy and safety of pharmacological therapies for PH in patients with ILD. Given the inherent complexity of diagnosing and managing heterogeneous ILD subtypes, there is a clear need for multidisciplinary and personalised care strategies for ILD-PH. Dedicated attention and further research to improve diagnostic and treatment interventions are warranted to help develop much-needed, evidence-based guidelines and to improve outcomes that are meaningful for patients with ILD-PH.
- 12 March 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2502651
Top Cited PapersOpen AccessPulmonary hypertension associated with interstitial lung disease: a state-of-the-art review
Pulmonary hypertension (PH) is a common sequela of interstitial lung diseases (ILDs) and is associated with poor prognosis and quality of life. The diagnosis and management of PH associated with ILD (ILD-PH) are challenging, due in part to the heterogeneity of ILD subtypes, difficulty distinguishing symptoms and signs of ILD progression from manifestations of PH, lack of specific biomarkers, and the requirement of invasive right heart catheterisation (RHC) to diagnose and assess the severity of PH. This state-of-the-art review provides a comprehensive overview of the clinical characteristics, pathophysiology, diagnosis, prognosis and treatment of ILD-PH. It also identifies promising areas for future research, such as the development and validation of novel biomarkers and imaging techniques and further evaluation of the efficacy and safety of pharmacological therapies for PH in patients with ILD. Given the inherent complexity of diagnosing and managing heterogeneous ILD subtypes, there is a clear need for multidisciplinary and personalised care strategies for ILD-PH. Dedicated attention and further research to improve diagnostic and treatment interventions are warranted to help develop much-needed, evidence-based guidelines and to improve outcomes that are meaningful for patients with ILD-PH.
- Open Access
- 22 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Assessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease
Interstitial lung disease (ILD)-related pulmonary hypertension (PH) is associated with high symptom burden and reduced quality of life, and has one of the worst prognoses of all PH subgroups [1, 2]. The onset of PH in patients with ILD is insidious and progressive [3]. Diagnosis remains challenging, as confirmation and stratification require invasive right heart catheterisation (RHC), where PH is defined by a mean pulmonary artery pressure >20 mmHg, with precapillary PH also having PCWP no more than 15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU) [1].
- 22 January 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (3)
Open AccessAssessment of noninvasive parameters prior to diagnosis of pulmonary hypertension in patients with fibrotic interstitial lung disease
Interstitial lung disease (ILD)-related pulmonary hypertension (PH) is associated with high symptom burden and reduced quality of life, and has one of the worst prognoses of all PH subgroups [1, 2]. The onset of PH in patients with ILD is insidious and progressive [3]. Diagnosis remains challenging, as confirmation and stratification require invasive right heart catheterisation (RHC), where PH is defined by a mean pulmonary artery pressure >20 mmHg, with precapillary PH also having PCWP no more than 15 mmHg and pulmonary vascular resistance (PVR) >2 Wood units (WU) [1].
- Open Access
- 18 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Deep-learning networks accurately detect pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Background: There is currently no widely used noninvasive tool that accurately predicts pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF). We aimed to assess the feasibility of developing deep-learning algorithms for detecting PH in patients with IPF. Methods: A retrospective derivation cohort included patients with IPF and PH and patients with IPF without PH, matched for age, sex and forced vital capacity (FVC%). Individual echocardiographic frames were split into a training and a validation set. The network consisted of three connected two-dimensional convolutional subnetworks; each one accepted an apical four-chamber view, a parasternal short-axis view and a lung computed tomography view from the same individual, respectively. The output was then merged with serum brain natriuretic peptide levels and diffusion lung capacity of carbon monoxide. Results: Overall, 65 patients with PH and IPF (68.6±7.2 years, 75.4% female, FVC 62.7%) and 65 matched patients without PH were included in the derivation cohort. A training set of 122 patients with and without PH revealed a >99% accuracy in detecting PH. A validation set demonstrated 87.5% accuracy per patient for correctly detecting PH (area under the curve (AUC) 0.971, 95% CI 00.521–1.000; p=0.0004; sensitivity 83.3%, specificity 100%). An external testing set of six patients with IPF and PH and six matched patients without PH showed 87.5% accuracy per patient (AUC 0.844, 95% CI 0.540–0.992; p=0.03; sensitivity 100%, specificity 75.0%). Conclusions: Deep-learning algorithms can accurately predict PH in patients with IPF. Further validation in a larger external cohort is warranted.
- 18 December 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Open AccessDeep-learning networks accurately detect pulmonary hypertension in patients with idiopathic pulmonary fibrosis
Background: There is currently no widely used noninvasive tool that accurately predicts pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF). We aimed to assess the feasibility of developing deep-learning algorithms for detecting PH in patients with IPF. Methods: A retrospective derivation cohort included patients with IPF and PH and patients with IPF without PH, matched for age, sex and forced vital capacity (FVC%). Individual echocardiographic frames were split into a training and a validation set. The network consisted of three connected two-dimensional convolutional subnetworks; each one accepted an apical four-chamber view, a parasternal short-axis view and a lung computed tomography view from the same individual, respectively. The output was then merged with serum brain natriuretic peptide levels and diffusion lung capacity of carbon monoxide. Results: Overall, 65 patients with PH and IPF (68.6±7.2 years, 75.4% female, FVC 62.7%) and 65 matched patients without PH were included in the derivation cohort. A training set of 122 patients with and without PH revealed a >99% accuracy in detecting PH. A validation set demonstrated 87.5% accuracy per patient for correctly detecting PH (area under the curve (AUC) 0.971, 95% CI 00.521–1.000; p=0.0004; sensitivity 83.3%, specificity 100%). An external testing set of six patients with IPF and PH and six matched patients without PH showed 87.5% accuracy per patient (AUC 0.844, 95% CI 0.540–0.992; p=0.03; sensitivity 100%, specificity 75.0%). Conclusions: Deep-learning algorithms can accurately predict PH in patients with IPF. Further validation in a larger external cohort is warranted.
- Open Access
- 16 October 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Survival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype
Pulmonary hypertension (PH) is common in patients with interstitial lung disease (ILD), observed in 7–15% of those with early idiopathic pulmonary fibrosis (IPF) [1] and in over 70% in those with late-stage disease [2]. PH drives an increase in mortality which appears independent of haemodynamic severity in patients with ILD-PH [3]. Historic ILD registries suggest that survival is dependent upon ILD subtype; for instance, overall survival in non-IPF subtypes, including nonspecific interstitial pneumonia (NSIP), greatly exceeds that of IPF [4].
- 16 October 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessSurvival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype
Pulmonary hypertension (PH) is common in patients with interstitial lung disease (ILD), observed in 7–15% of those with early idiopathic pulmonary fibrosis (IPF) [1] and in over 70% in those with late-stage disease [2]. PH drives an increase in mortality which appears independent of haemodynamic severity in patients with ILD-PH [3]. Historic ILD registries suggest that survival is dependent upon ILD subtype; for instance, overall survival in non-IPF subtypes, including nonspecific interstitial pneumonia (NSIP), greatly exceeds that of IPF [4].
- 8 May 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2401830
Drugs targeting novel pathways in pulmonary arterial hypertension
Over the past three decades, several drugs have been developed to target three major dysfunctional pathways in PAH, including the prostacyclin, endothelin, and nitric oxide pathways. Despite these advances, PAH remains incurable, necessitating further drug discovery efforts. New therapies focus on previously untargeted pathways, especially the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-β) signalling pathway. Dysregulation of this pathway, involving the Smad2/3 and Smad1/5/8 signalling branches, plays a key role in pulmonary vascular remodelling. Sotatercept, a fusion protein acting as an activin receptor ligand trap to rebalance growth-promoting and growth-inhibiting signalling has shown promise in clinical trials by reducing pulmonary vascular resistance and improving exercise capacity. Other emerging treatments aim to restore balance within the BMP/TGF-β pathway. Therapies targeting receptor tyrosine kinases (RTKs), such as imatinib, inhibit the platelet-derived growth factor pathway. Though oral imatinib has shown efficacy, its side effects have limited widespread use. Additional strategies exploring lower doses of imatinib and novel delivery methods, such as inhalation, to reduce systemic side effects failed to demonstrate clinical benefit. Novel RTK inhibitors like seralutinib administered by inhalation have shown promising results in a phase 2 clinical trial. Other emerging approaches include anti-inflammatory therapies, hormonal modulation, and metabolism-targeting agents like ranolazine and SGLT2 inhibitors, which could expand the therapeutic landscape for PAH. Overall, the continued development of novel drugs targeting these pathways offers hope for better disease management and improved outcomes for patients with PAH.
- 8 May 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- p. 2401830
Drugs targeting novel pathways in pulmonary arterial hypertension
Over the past three decades, several drugs have been developed to target three major dysfunctional pathways in PAH, including the prostacyclin, endothelin, and nitric oxide pathways. Despite these advances, PAH remains incurable, necessitating further drug discovery efforts. New therapies focus on previously untargeted pathways, especially the bone morphogenetic protein (BMP)/transforming growth factor-beta (TGF-β) signalling pathway. Dysregulation of this pathway, involving the Smad2/3 and Smad1/5/8 signalling branches, plays a key role in pulmonary vascular remodelling. Sotatercept, a fusion protein acting as an activin receptor ligand trap to rebalance growth-promoting and growth-inhibiting signalling has shown promise in clinical trials by reducing pulmonary vascular resistance and improving exercise capacity. Other emerging treatments aim to restore balance within the BMP/TGF-β pathway. Therapies targeting receptor tyrosine kinases (RTKs), such as imatinib, inhibit the platelet-derived growth factor pathway. Though oral imatinib has shown efficacy, its side effects have limited widespread use. Additional strategies exploring lower doses of imatinib and novel delivery methods, such as inhalation, to reduce systemic side effects failed to demonstrate clinical benefit. Novel RTK inhibitors like seralutinib administered by inhalation have shown promising results in a phase 2 clinical trial. Other emerging approaches include anti-inflammatory therapies, hormonal modulation, and metabolism-targeting agents like ranolazine and SGLT2 inhibitors, which could expand the therapeutic landscape for PAH. Overall, the continued development of novel drugs targeting these pathways offers hope for better disease management and improved outcomes for patients with PAH.
Dietary nitrate supplementation enhances exercise capacity in WHO Group 3 pulmonary hypertension: a double-blind, placebo-controlled, randomised crossover study (EDEN-OX2)
Dietary nitrate supplementation, which improves skeletal muscle oxygen utilisation, vascular endothelial function and exercise capacity in people with chronic obstructive pulmonary disease, may benefit other lung conditions. In a double-blind, placebo-controlled, crossover study, in 19 adults with Group 3 pulmonary hypertension who desaturated during exercise, 140 mL of nitrate-rich beetroot juice improved endurance shuttle walk time compared with nitrate-depleted beetroot juice placebo (median (IQR) ESWT NR-BRJ 197 (140–273) s vs PL-BRJ 174 (107–229) s; median difference (MD) (95% CI) 30 (6.19 to 91.07) s, p=0.0281), endothelial function, flow-mediated dilatation (+3.40±5.47% vs −1.33±4.78; MD (95% CI) 4.73 (1.44 to 8.02), p=0.007) and lowered mean arterial blood pressure (−3.9 (−7.4 to −0.4) mm Hg, p=0.028).
Dietary nitrate supplementation enhances exercise capacity in WHO Group 3 pulmonary hypertension: a double-blind, placebo-controlled, randomised crossover study (EDEN-OX2)
Dietary nitrate supplementation, which improves skeletal muscle oxygen utilisation, vascular endothelial function and exercise capacity in people with chronic obstructive pulmonary disease, may benefit other lung conditions. In a double-blind, placebo-controlled, crossover study, in 19 adults with Group 3 pulmonary hypertension who desaturated during exercise, 140 mL of nitrate-rich beetroot juice improved endurance shuttle walk time compared with nitrate-depleted beetroot juice placebo (median (IQR) ESWT NR-BRJ 197 (140–273) s vs PL-BRJ 174 (107–229) s; median difference (MD) (95% CI) 30 (6.19 to 91.07) s, p=0.0281), endothelial function, flow-mediated dilatation (+3.40±5.47% vs −1.33±4.78; MD (95% CI) 4.73 (1.44 to 8.02), p=0.007) and lowered mean arterial blood pressure (−3.9 (−7.4 to −0.4) mm Hg, p=0.028).
- 10 October 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (4) , 2401087
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!
Shareable abstract The proteasome inhibitor myeloma therapy, carfilzomib, is an increasingly reported cause of drug-induced PAH, which can be reversible. This case highlights the complexity of close monitoring for further pulmonary vascular complications during follow-up. https://bit.ly/3yvHxpk
- 10 October 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (4) , 2401087
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!
Shareable abstract The proteasome inhibitor myeloma therapy, carfilzomib, is an increasingly reported cause of drug-induced PAH, which can be reversible. This case highlights the complexity of close monitoring for further pulmonary vascular complications during follow-up. https://bit.ly/3yvHxpk